Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

Capital Medical University

Status: Enrolling

Conditions: Moyamoya Disease

Treatments: Procedure: Revascularization

Study type: Observational

Funder types: Other

Identifiers

NCT06832839

KY2024-112-02

Details and patient eligibility

About

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Full description

Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.

Enrollment: 360 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
• Please sign the informed consent form.
• Participants must be between 18 and 60 years of age.

Exclusion criteria

• Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
• Individuals younger than 18 years or older than 60 years.
• Those with contraindications for magnetic resonance imaging.
• Patients who are unable to complete cognitive brain assessments